The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InModerna (MRNA) shares face significant pressure following the U.S. Food and Drug Administration's (FDA) refusal to review the company's application for its experimental mRNA-1010 flu vaccine. The regulatory agency issued a 'refusal to review' letter, citing fundamental concerns regarding the study's design and a lack of adequate, well-controlled data. This setback is compounded by a strategic pivot from the Department of Health and Human Services (HHS), which announced plans to wind down mRNA vaccine development and terminate related contracts. The HHS shift indicates a broader policy move away from mRNA platforms in favor of alternative vaccine technologies for respiratory infections. Analysts view this development as a major blow to Moderna’s pipeline, potentially threatening its long-term revenue growth and market valuation. The news has also triggered broader concerns across the biotechnology sector, impacting other mRNA-focused firms like BioNTech and Pfizer.